Cynata Therapeutics Ltd (CYYNF) Stock Price, Trades & News

Cynata Therapeutics Ltd is engaged in the development and commercialization of a proprietary mesenchymal stem cell (MSC) technology for potential human therapeutic use, which is branded as Cymerus manufacturing platform. There are currently three active clinical trials taking place using Cymerus technology, which are attempting to treat osteoarthritis and others.

Financial Strength

Name	Current	Vs Industry
Cash-To-Debt	No Debt
Equity-to-Asset	0.75
Interest Coverage	No Debt
Piotroski F-Score	2/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year EBITDA Growth Rate	16.7
	3-Year EPS without NRI Growth Rate	-6.6
	3-Year FCF Growth Rate	-23.2
	3-Year Book Growth Rate	-46.2
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-439.97

Momentum Rank

	Name	Current	Vs Industry		Vs History
	9-Day RSI	0.02
	14-Day RSI	0.09
	3-1 Month Momentum %	1.14
	6-1 Month Momentum %	48.33
	12-1 Month Momentum %	178.13

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	2.48
	Quick Ratio	2.48
	Cash Ratio	2.3

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-16.4
	Shareholder Yield %	-2.6

Profitability Rank

	Name	Current	Vs Industry		Vs History
	ROE %	-120.87
	ROA %	-102.6
	ROIC %	-487.59
	3-Year ROIIC %	-425.82
	ROCE %	-148.31
	Moat Score	4
	Tariff Resilience Score	4

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PB Ratio	0.08
	Price-to-Tangible-Book	0.08
	EV-to-Forward-Revenue	13.14
	Price-to-Net-Current-Asset-Value	0.08
	Price-to-Net-Cash	0.08
	FCF Yield %	-298.16

Financials (Next Earnings Date:2027-02-26 Est.)

Annual Quarterly TTM

CYYNF's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Gurus Latest Trades with OTCPK:CYYNF

No Available Data

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Cynata Therapeutics Ltd Executives

Details

GF Value™

CYYNF

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with CYYNF. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil $)
	EPS (TTM) ($)	-0.025
	Beta	-0.8321
	3-Year Sharpe Ratio	0.34
	3-Year Sortino Ratio	0.56
	Volatility %	78.64
	14-Day RSI	0.09
	14-Day ATR ($)	0.01135
	20-Day SMA ($)	0.169125
	12-1 Month Momentum %	178.13
	52-Week Range ($)	0.009 - 0.2225
	Shares Outstanding (Mil)	243.45

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	2
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Cynata Therapeutics Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Cynata Therapeutics Ltd Stock Events

Financials Calendars

Event	Date	Price ($)
General meeting for 2026	2026-11-13 10:00	In 140 days
Annual report for 2026	2026-08-28	In 62 days
Second quarter earnings results for 2026	2026-02-26	0.22 (+0.00%)
Cynata Quarterly Investor Webinar	2026-02-04 11:30	0.22 (+0.00%)
General meeting for 2025	2025-11-13 10:00	0.12 (+0.00%)
Annual report for 2025	2025-08-28	0.12 (+0.00%)
Second quarter earnings results for 2025	2025-02-27	0.14 (+0.00%)
General meeting for 2024	2024-11-19 10:00	0.19 (+0.00%)
Annual report for 2024	2024-08-29	0.19 (+0.00%)
Fourth quarter earnings results for 2024	2024-07-29	0.19 (+0.00%)

Show

Entries

Cynata Therapeutics Ltd Frequently Asked Questions

What is Cynata Therapeutics Ltd(CYYNF)'s stock price today?

The current price of CYYNF is $0.01. The 52 week high of CYYNF is $0.22 and 52 week low is $0.01.

When is next earnings date of Cynata Therapeutics Ltd(CYYNF)?

The next earnings date of Cynata Therapeutics Ltd(CYYNF) is 2027-02-26 Est..

Does Cynata Therapeutics Ltd(CYYNF) pay dividends? If so, how much?

Cynata Therapeutics Ltd(CYYNF) does not pay dividend.

Guru Commentaries on OTCPK:CYYNF

No articles.

Press Release

	Subject	Date
	Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial	2025-12-14
	CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial	2024-12-04
	Further CYP-001 GvHD Clinical Data Published in Nature Medicine	2024-05-22
	Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial	2024-04-07
	First Patient Treated in Phase 2 GvHD Trial	2024-03-04
	Encouraging Initial Data from CYP-006TK Diabetic Foot Ulcer Clinical Trial	2024-02-26
	Dimension Inx announces the addition of biotech industry leaders Paul K. Wotton, Ph.D., as Board Director and Chris Ehrlich as Senior Advisor	2023-05-02
	LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation	2022-11-04
	US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD	2022-07-15
	US FDA Clears IND for Cynata's Phase 2 Clinical Trial of CYP-001 in GvHD	2022-07-05

10/Page

Articles on Cynata Therapeutics Ltd

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.